Agios Pharmaceuticals (NASDAQ:AGIO) was upgraded by ValuEngine from a “sell” rating to a “hold” rating in a research note issued on Sunday, December 31st.
Other research analysts also recently issued research reports about the company. Oppenheimer set a $83.00 price target on Agios Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, December 26th. SunTrust Banks reiterated a “buy” rating and set a $80.00 target price on shares of Agios Pharmaceuticals in a report on Wednesday, October 4th. JPMorgan Chase & Co. reiterated a “buy” rating and set a $76.00 target price on shares of Agios Pharmaceuticals in a report on Monday, September 18th. Canaccord Genuity set a $90.00 target price on Agios Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, December 12th. Finally, Cann reiterated a “buy” rating on shares of Agios Pharmaceuticals in a report on Tuesday, December 5th. One analyst has rated the stock with a sell rating, two have given a hold rating and twelve have given a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $75.00.
Shares of Agios Pharmaceuticals (AGIO) opened at $67.34 on Friday. Agios Pharmaceuticals has a 52 week low of $39.24 and a 52 week high of $72.73. The firm has a market capitalization of $3,280.00, a PE ratio of -10.74 and a beta of 1.83.
Agios Pharmaceuticals (NASDAQ:AGIO) last released its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.78) by $0.19. Agios Pharmaceuticals had a negative return on equity of 69.64% and a negative net margin of 506.39%. The company had revenue of $11.35 million during the quarter, compared to analyst estimates of $10.85 million. During the same quarter in the previous year, the company posted ($1.63) EPS. Agios Pharmaceuticals’s revenue for the quarter was up 26.4% on a year-over-year basis. equities analysts anticipate that Agios Pharmaceuticals will post -6.59 earnings per share for the current year.
In related news, insider Scott Biller sold 2,146 shares of the stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $62.69, for a total value of $134,532.74. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Lewis Clayton Jr. Cantley sold 3,838 shares of the stock in a transaction dated Thursday, December 7th. The shares were sold at an average price of $59.37, for a total transaction of $227,862.06. Following the completion of the transaction, the director now directly owns 80,851 shares of the company’s stock, valued at approximately $4,800,123.87. The disclosure for this sale can be found here. Insiders have sold a total of 29,130 shares of company stock worth $1,844,260 over the last three months. Insiders own 5.43% of the company’s stock.
Several large investors have recently made changes to their positions in AGIO. Hood River Capital Management LLC lifted its stake in Agios Pharmaceuticals by 2.3% in the second quarter. Hood River Capital Management LLC now owns 118,844 shares of the biopharmaceutical company’s stock worth $6,115,000 after purchasing an additional 2,626 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in Agios Pharmaceuticals by 4.9% in the second quarter. Goldman Sachs Group Inc. now owns 681,093 shares of the biopharmaceutical company’s stock worth $35,042,000 after purchasing an additional 31,969 shares during the last quarter. Virtu KCG Holdings LLC bought a new stake in Agios Pharmaceuticals in the second quarter worth about $743,000. Royal Bank of Canada lifted its stake in Agios Pharmaceuticals by 40.8% in the second quarter. Royal Bank of Canada now owns 9,131 shares of the biopharmaceutical company’s stock worth $470,000 after purchasing an additional 2,648 shares during the last quarter. Finally, Utah Retirement Systems lifted its stake in Agios Pharmaceuticals by 35.7% in the second quarter. Utah Retirement Systems now owns 7,600 shares of the biopharmaceutical company’s stock worth $391,000 after purchasing an additional 2,000 shares during the last quarter. 93.79% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This report was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/01/11/agios-pharmaceuticals-agio-upgraded-to-hold-at-valuengine.html.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.